Abstract 309P
Background
The American College of radiology proposed BI-RADS lexicon lacks defined rules which direct conversion of specific imaging features into a diagnostic category, results in a discrepancy of reporting. This study compares results from multilayer Perceptron neural network and a classification tree.
Methods
A total of 316 lesions with successive histological verification (221 malignant, 95 benign) were investigated. Six lesion criteria's were assessed by 2 readers in consensus. Classification analysis was performed using the chi-squared automatic interaction detection (CHAID) method. Results include the probability for malignancy for every descriptor combination in the classification tree. Simultaneously a multilayer Perceptron neural network was developed by using SPSS software.
Results
A classification tree incorporating 6 lesion descriptors with a depth of 4 ramifications (1- ADC values; 2 -root sign; 3- enhancement pattern; 4 - oedema) was calculated. Of all 316 lesions, 38 (40 %) and 212 (95.9 %) could be classified as benign and malignant with an accuracy above 95 %, respectively. Overall diagnostic accuracy was 79.1 %. The multilayer perceptron network segregated the lesions into training and testing sets in a ratio of 7:3. With a hyperbolic tangent activation function, there were six units of hidden layer and the model show a 20% and 17% incorrect predictions in the training in the testing sets. The diagnostic accuracy of malignant and benign lesions was 92% and 52 % in both the training and testing sets. The area under the curve of the ROC was .855. The order of importance of synaptic weights calculated from the model were ADC ( 0.257), Internal enhancement (0.233), ROOT SIGN (0.175), Margins (0.138), Curve type (0.138), edema (0.038) and mass / non mass (0.021).
Conclusions
The classification algorithm correctly classified 95 % malignant lesions with accuracy above 95 %. The neural network model showed good results on internal validation and revealed ADC to be the most significant parameter with the least importance to morphological classification into mass and non-mass lesions. Also, the dynamic contrast curve patterns were more significant than margins.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi Cancer Institute and Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session
174P - A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study
Presenter: Wenwen Zhang
Session: e-Poster Display Session
175P - A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)
Presenter: Yanhong Gu
Session: e-Poster Display Session
177P - Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
Presenter: Hui-Chuan Sun
Session: e-Poster Display Session
178P - Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
Presenter: Jaekyung Cheon
Session: e-Poster Display Session
179P - Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy
Presenter: Yue Han
Session: e-Poster Display Session
180P - Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)
Presenter: Su Pin Choo
Session: e-Poster Display Session
181P - Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis
Presenter: Weihua Zhi
Session: e-Poster Display Session
182P - Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study
Presenter: Qi Li
Session: e-Poster Display Session